SLC5A2 and neoplasm: These hypoxic areas in the tumor are usually resistant to the chemotherapeutic agents [13]. Hence, this suggests that SGLT2 inhibitors could be combined with the chemotherapeutic agents to enhance the anti-proliferative effect in PDAC.